Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment

Oncologist

Volumn 19, Issue 9, 2014, Pages 1008-1010

  Klempner, Samuel J ^a   Aubin, Golnaz ^a   Dash, Atreya ^b   Ignatius Ou, Sai Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; FLUORODEOXYGLUCOSE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; BACTERIURIA; CASE REPORT; DISEASE SURVEILLANCE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KIDNEY CYST; MIDDLE AGED; NOTE; PHASE 2 CLINICAL TRIAL; RADIOGRAPHY; REMISSION; STAPHYLOCOCCUS; STREPTOCOCCUS; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; COMPLICATION; CYST; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES, CYSTIC; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CYSTS; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES, CYSTIC; MIDDLE AGED; PYRAZOLES; PYRIDINES;

EID: 84906974650     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0216     Document Type: Note

References (9)

1. Ou SHI, Bartlett CH, Mino-Kenudson M et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the seconddecade of molecular targetedtherapyinoncology. The Oncologist 2012; 17:1351-1375.
2. XALKORI U.S. Physician Prescribing Information. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id=676. Accessed May 15, 2014.
3. Ou SHI, Jänne PA, Bartlett CH et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-422.
4. Tada S, Yamagishi J, Kobayashi H et al. The incidence of simple renal cyst by computed tomography. Clin Radiol 1983;34:437-439.
5. Bosniak MA. The current radiological approach to renal cysts. Radiology 1986;158:1-10.
6. Whelan TF. Guidelines on the management of renal cyst disease. Can Urol Assoc J 2010;4:98-99.
7. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
8. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
9. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.